Alzamend Neuro, INC 8-K filings

Alzamend Neuro, Inc. announced a $25 million securities purchase agreement for Series D convertible preferred stock and addressed Nasdaq's majority independent board standard non-compliance.

Alzamend Neuro, Inc. announced the passing of its director, Lynne Fahey McGrath, M.P.H., Ph.D., who died on July 20, 2026.

Stockholders of Alzamend Neuro, Inc. authorized a reverse stock split and approved a new 2025 Stock Incentive Plan during the annual meeting.

Alzamend Neuro, Inc. has entered into an At-the-Market Issuance Sales Agreement to sell up to $3.0 million of common stock.

Alzamend Neuro announced the passing of director Andrew H. Woo, M.D., Ph.D., who had served on the board since its 2021 IPO.

Alzamend Neuro, Inc. has officially eliminated its Series B and Series C convertible preferred stock designations, simplifying its capital structure.

Alzamend Neuro, Inc. issued 361,743 shares of common stock between October 1 and October 8, 2025, through the conversion of Series B Convertible Preferred Stock.

Alzamend Neuro, Inc. issued 300,000 shares of common stock through the conversion of Series B Convertible Preferred Stock, increasing its outstanding common shares to 3,439,861.

Alzamend Neuro, Inc. announced the issuance of 243,429 common shares through the conversion of Series B Convertible Preferred Stock, increasing total common shares outstanding to 3,139,861.

Alzamend Neuro announced its annual 2025 financial results, showcasing a strengthened financial position and progress in its AL001 clinical programs, despite facing delays in its ALZN002 trial due to CRO issues.

Alzamend Neuro, Inc. has officially eliminated its Series A convertible preferred stock, simplifying its capital structure following the conversion or reacquisition and cancellation of all previously issued shares.

Alzamend Neuro implements a one-for-nine reverse stock split effective May 12, 2025, to maintain Nasdaq Capital Market listing compliance.

Alzamend Neuro successfully held its annual meeting on April 25, 2025, electing eight directors and approving proposals related to auditor ratification, preferred stock conversion, and a potential reverse stock split.

Alzamend Neuro updates its bylaws to reduce the quorum requirement for stockholder meetings and establishes a new Series C Convertible Preferred Stock.

Alzamend Neuro enters into an agreement with Orchid Finance LLC, issuing warrants to purchase one million shares of common stock as part of a securities purchase and exchange agreement.

Alzamend Neuro announced a strengthened financial position with increased stockholder equity and cash, alongside plans to initiate five clinical trials in 2025.

Alzamend Neuro has successfully regained compliance with Nasdaq listing standards after demonstrating it met the minimum stockholders' equity requirement.

Alzamend Neuro has entered into an agreement to sell up to $6.5 million of its common stock through an at-the-market offering.

Alzamend Neuro has successfully regained compliance with Nasdaq's minimum bid price requirement, avoiding potential delisting.

Alzamend Neuro has announced a one-for-ten reverse stock split of its common stock, effective July 16, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Alzamend Neuro stockholders approved the conversion of Series A Preferred Stock into common stock and warrants at a special meeting on July 8, 2024.

Alzamend Neuro has been granted an extension by the Nasdaq Hearings Panel to maintain its listing, contingent on achieving a minimum stockholder equity of $2.5 million by September 23, 2024.

Alzamend Neuro has updated its investor presentation, showcasing advancements in its therapeutic drug candidates for neurodegenerative and psychiatric disorders, including Alzheimer's disease.

Alzamend Neuro successfully obtained shareholder approval for the issuance of additional shares related to the Series B transaction at an adjourned annual meeting on May 13, 2024.

Alzamend Neuro closed an initial tranche of a financing agreement, raising $1 million through the sale of preferred stock and warrants.

Alzamend Neuro has entered into an agreement for a registered direct offering and concurrent private placement, potentially raising up to $25 million.

Alzamend Neuro, Inc. has dismissed Baker Tilly US, LLP and appointed Haskell & White LLP as its new independent registered public accounting firm, effective May 5, 2024.

Alzamend Neuro has terminated its at-the-market equity offering program, effective May 16, 2024, after raising approximately $1.3 million.

Alzamend Neuro's annual meeting saw the election of eight directors, ratification of the accounting firm, and approval of a reverse stock split, but a vote on a share issuance was adjourned to May 13, 2024.

Alzamend Neuro has finalized an additional closing with Ault Lending, bringing total funding to $2.1 million, and issued a $310,000 promissory note to an accredited investor.